Today: 8 June 2026
Browse Category

TSX:AG 26 November 2025 - 14 February 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 14.02.2026

First Majestic Silver shares rose 6.4% in a day and 13.6% this month, now up 85.53% over 90 days. The stock trades at CA$31.28, with some analysts valuing it as high as CA$120, while a discounted cash flow model puts fair value at CA$30.03. Debate continues over valuation and risks tied to production and cost controls after the Gatos acquisition.
14 February 2026
·
First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver shares hit a 52-week high of $16.30 on December 11, trading near $16.50 intraday, after silver prices reached all-time highs. The stock is up about 185–190% year-to-date, lifting market cap to $7.5–8.0 billion. Q3 2025 saw record silver production of 3.9 million ounces and EBITDA of $128.6 million. Net earnings reached $43 million, reversing a loss from last year.
11 December 2025
···
First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

First Majestic Silver shares traded near $15.40 on December 10, 2025, close to their 52-week high, after more than doubling year-to-date. Spot silver surged past $60 an ounce for the first time, driven by supply deficits and strong industrial demand. The company reported record production and earnings, and completed a $350 million convertible note offering. Market cap stands near $7.6 billion.
10 December 2025
···

Stock Market Today

  • SpaceX, OpenAI, Anthropic IPOs in 2026: Market Absorption Challenge
    June 8, 2026, 10:15 AM EDT. SpaceX, OpenAI, and Anthropic plan public listings in 2026 with combined valuations near $4 trillion. SpaceX leads with a Nasdaq IPO priced at $135 per share, aiming to raise a record $75 billion. This surpasses Saudi Aramco's 2019 record for capital raised in an initial public offering. The market's capacity to absorb these mega-IPOs is under scrutiny, with index providers easing benchmark entry rules to accommodate rapid share accumulation. Investment banks such as Goldman Sachs and Morgan Stanley are spearheading the SpaceX deal. While investor demand appears strong, analysts expect a challenging absorption period given the unprecedented scale.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Go toTop